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Abstract
Purpose Patients with malignancy sometimes develop
painful mucositis and require patient-controlled analgesia
(PCA) to treat their pain. Pain disrupts sleep and there is
some evidence that analgesic medications also disrupt
sleep. This study examined whether treatment with the
sedative hypnotic eszopiclone could improve self-reports of
sleep, fatigue, and pain as well as decrease opioid self-
administered via PCA.
Methods Inpatients who developed mucositis severe
enough to require PCA treatment were randomized
double-blind to a 2-day trial on eszopiclone or placebo-
administered at bedtime. Patients completed questionnaires
which assessed sleep, pain, and fatigue. PCA medication
was calculated in terms of morphine equivalents. Data were
analyzed with unpaired t tests and repeated measures
analysis of variance.
Results Twenty-two patients were randomized to placebo
and 23 to eszopiclone. Groups were comparable in age and
treatment characteristics. Mean pain scores were lower in
the eszopiclone group at all time points (morning p=0.01,
afternoon p=0.04, evening p=0.04). The eszopiclone group
reported increased sleep time (p<0.05), fewer nighttime
awakenings (p<0.001), better self-reported sleep quality (p=
0.01), and depth (p=0.04). There were no significant
differences between eszopiclone and placebo in terms of
self-reports of fatigue or opioid usage.
Conclusion Sedative hypnotic agents improve sleep and
analgesia even in the setting of considerable pain and
discomfort.
Keywords Pain.Sleep.Fatigue.Opioids.Eszopiclone.
Sedative hypnotics.Patient-controlled analgesia.
Mucositis.Cancer
Introduction
Pain, insomnia, and fatigue are common symptom com-
plaints of cancer patients. Although dramatic improvements
have come about in recognizing and treating cancer related
pain, less progress has been made in treating fatigue or
sleep disorders.
Patients with malignancy who develop moderate to
severe pain are commonly treated with opioids. One of
the less commonly recognized side effects of opiate use is
sleep disruption [1]. Although the human literature is small,
it is clear that opiates, while sedating, are also profoundly
sleep disruptive. We previously reported that opiate use
significantly increased light sleep and decreased deep sleep
[2]. Sleep disruption lowers pain threshold [3], and opioid
medications themselves disrupt deep sleep [4], thereby
putting in place a potential vicious cycle of pain, insomnia,
more pain, and more insomnia. The quality of sleep
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nighttime sleep [5–7]. Animal and human studies demon-
strate that experimentally induced sleep disruption lowers
the threshold for detection of painful stimuli [8–10].
Although opiates are obviously helpful for pain, they do
so at certain “costs”: They increase next day fatigue,
constipation, and other side effects; they disrupt sleep
which further increases next day fatigue; and finally, by
virtue of their sleep disruptive properties, they lower the
threshold for pain stimuli, thereby insuring that continuing
or even higher doses of opiates are required.
Oral mucositis is a particularly painful side effect of
certain types of chemotherapy [11–13]. High-dose melpha-
lan used in autologous stem cell transplantation for multiple
myeloma and malignant lymphoma is a frequent cause of
mucositis. Total body irradiation (TBI) is also commonly
associated with mucositis when patients receive TBI in
conjunction with myeloablative allogeneic stem cell trans-
plantation. Mucositis is commonly treated with opiates and,
if severe, with patient-controlled analgesia (PCA) devices.
These devices are advantageous because they allow smooth
safe parenteral dosing of opiates to patients in moderate to
severe pain. A baseline continuing infusion of opiate is
programmed, and the device allows a certain amount of prn
self-medication administration for additional pain relief.
With PCAs, opiate usage can be quantitated in terms of
morphine equivalents per 24 h or in smaller time intervals
(e.g., nighttime vs daytime).
Eszopiclone (Lunesta™) is a non-benzodiazepine hyp-
notic agent used for treatment of insomnia. Roth et al.
recently reported that eszopiclone improved pain reports in
insomniac patients who also suffered from rheumatoid
arthritis [14]. Because patients with extensive mucositis
commonly experience severe pain, we wondered if a
hypnotic agent might improve their pain. This study
examined the effect of eszopiclone on sleep, pain, and
fatigue in patients with hematologic malignancy undergo-
ing chemotherapy and/or hematopoietic stem cell trans-
plantation. The study also examined if eszopiclone
treatment would lead to decreased opioid requirements via
PCA in these patients.
Methods
The study was approved by the UCSD IRB and is a
registeredclinical trial (ClinicalTrials.gov#NCT00365261).
Patient eligibility
Patients were eligible for participation if they required
inpatient hospitalization for hematologic malignancy, if
they were between 20 and 75 years old, were able to
tolerate oral medication, and were able to provide informed
consent. Patients were excluded if they had a current
history of substance abuse, had a history of allergic
response to eszopiclone, required additional oral or paren-
teral opioids after starting PCA opioid treatment, or were
regularly taking a prescribed sleeping pill more often than
four times per week.
These patients were variously diagnosed with acute and
chronic myeloid leukemia, multiple myeloma, Waldenstrom’s
macroglobulinemia, Pre-B acute lymphoblastic leukemia,
diffuse large B cell lymphoma, T cell lymphoma, and T
cell pro-lymphocytic lymphoma. Patients were treated
with (1) high-dose melphalan, (2) cytosine arabinoside
(total body irradiation), and (3) the BEAM regimen
comprising of busulfan, etoposide, cytosine arabinoside,
and melphalan.
Procedures
Inpatients at UCSD’s Thornton Hospital who were felt to
be at risk for developing mucositis were approached upon
admission and invited to participate in the study. Written
informed consent was obtained.
One hundred three inpatients were approached before
they developed painful mucositis. Two declined to partic-
ipate, 48 never developed mucositis, seven were ineligible,
and one patient was missed (see flow chart, Fig. 1). Forty-
five patients were enrolled and randomized to treatment.
Dosing Medications were administered double-blind for
two successive days on this parallel group design study.
Patients received eszopiclone 3 mg (or placebo) at 9 p.m.
Patients who were >64 years or individuals receiving potent
3A4 inhibitors such as ketoconazole received 2 mg eszo-
piclone. These doses are commonly employed and the dose
adjustment for older patients and for patients receiving 3A4
inhibitors is suggested in the prescribing information.
Active and placebo medications were obtained from
Sepracor and randomization, and blinding was provided
by the UCSD Research Pharmacy.
Self-report data Upon enrolling in the study, patients were
familiarized with the brief subjective report instruments.
Patients were asked to rate their pain and fatigue every 6 h
after dosing, while awake. Pain was assessed with a 10-cm
visual analog scale (0=“no pain at all”;1 0 = “severe,
uncontrolled pain”). Patients completed the five-item
Profile of Mood States Scale, Short Form (POMS-SF)
Fatigue–Inertia Scale [15] to rate their fatigue complaints
(higher scores denote more fatigue). Sleep quality was
assessed every morning by self-report. Sleep latency was
defined as the number of minutes taken to fall asleep after
bedtime. Patient were also asked how long they slept as
2016 Support Care Cancer (2011) 19:2015–2020well as how many times they woke during the night. In
addition, they rated their depth and quality of sleep (on a
scale of 0 (poor) to 10 (excellent)), as well as their current
level of sleepiness (0=very sleepy to 10=not sleepy at all).
PCA dosing PCAs were programmed to deliver either
morphine or dilaudid at fixed rate with optional self-
administered prn boluses. Medication was summarized per
nursing shift, and dilaudid doses were converted into
morphine equivalents by multiplying the dose by 5.
Statistical analysis Data were analyzed with two-sample
tests and repeated measures analysis of variance.
Results
Forty-five patients were randomized: 22 to group
placebo and 23 to group eszopiclone. Groups were
comparable in age (mean (SD): eszopiclone arm 45.52
(2.72) years vs placebo 46.00 (3.38) years; p=0.91) and
treatment (e.g., allotransplantation vs autotransplantation
p=0.92).
Side effects Three patients in each group received only one
dose of medication because of drowsiness or confusion.
There were no other side effects. Table 1 provides summary
data from the study.
Fig. 1 Patient flow diagram
Support Care Cancer (2011) 19:2015–2020 2017Sleep and fatigue effects The eszopiclone group reported
increased sleep time (p<0.05), fewer nighttime awakenings
(p<0.001), better self-reported sleep quality (p=0.01), and
depth (p=0.04; see Table 1 and Fig. 2). There were no
significant differences between the groups in terms of
sleep latency (p=0.52) or current level of sleepiness (p=
0.38). There was no significant difference between the
groups in terms of fatigue reports (see Table 1).
Pain effects Mean pain scores over the course of 2 days’
treatment were significantly lower in the eszopiclone group
than the placebo group (see Fig. 3 and Table 1) in the
morning (p=0.01), in the afternoon (p=0.04), as well as in
the evening (p=0.04).
Effects on PCA usage There were no significant differences
in terms of opiate usage: Median levels (25%, 75%) were
40.94 (23.37, 66.19) mg morphine in the placebo arm vs
36.35 mg (17.57, 58.46) in the eszopiclone arm (p=0.73
using Wilcoxon rank sum test).
Discussion
The central finding of this study was that eszopiclone led to
significant reductions in self-reported pain throughout the
day. However, no effect of eszopiclone was observed on
dose of opiates self-administered via PCA. If the analgesic
effect of eszopiclone were due just to drug carry-over and
sedation, one might expect the effect to be apparent only on
the morning ratings of pain. However, Fig. 3 reveals that,
after eszopiclone, pain ratings were consistently lower on
the next morning, afternoon, and evening. Furthermore, as
Table 1 reveals, fatigue scores were not significantly
different between the eszopiclone and placebo groups at
any of the three time points and, if anything, the
eszopiclone group had lower fatigue complaints. Thus, the
effects of eszopiclone on pain does not appear to reflect
sedative effects of the compound.
The study also confirmed that eszopiclone improved
subjective estimates of sleep, even in a group of patients
who were very ill and in pain. While it is not surprising to
detect an effect of a hypnotic agent on sleep [16], it is
important to keep in mind that insomnia is common and
demoralizing to patients and that insomnia in the context of
serious medical illness is all the more burdensome.
In future studies, it may be desirable to assess sleep via
polysomnography to determine which aspects of objectively
measured sleep are most associated with the beneficial
effects of eszopiclone on pain. Such data may help inform
future research because sedative hypnotic agents act via
diverse mechanisms, and it is thus possible that some agents
may be more effective in relieving pain. Insomnia (lack of
refreshing sleep) is defined on the basis of subjective
estimates of sleep. It is an interesting theoretical question
whether the beneficial effects of a sedative hypnotic agent on
pain and self-reported sleep stem from specific actions on
sleep physiology or on patient recall. Certainly, an extensive
basic science literature demonstrates that sleep disruption
increases pain sensitivity (see for instance [3]).
The study is limited by its small sample size. It is
possible that comparisons of borderline significance (i.e., p<
0.15) might reach conventional criteria of significance with
a larger sample size, but, in our study, with the exception of
afternoon fatigue levels (p=0.11), at no other time points
was eszopiclone associated with markedly lower levels of
fatigue. Sleep and fatigue are overlapping but distinct
constructs [17]. In this study, their dissociation was
beneficial to patients, i.e., patients reported improved sleep
without reporting increasing levels of daytime fatigue.
The PCA contrasts revealed no differences between the
groups. There was a large variance in PCA usage which is
Variable Eszopiclone Placebo p value
d
Mean (SEM) Mean (SEM)
Pain score
a Morning 3.72 (0.38) 5.41 (0.47) 0.01
Range 1–10 Afternoon 3.65 (0.45) 5.05 (0.49) 0.04
Evening 3.42 (0.49) 4.79 (0.43) 0.04
Fatigue score
a Morning 2.41 (0.20) 2.77 (0.17) 0.17
POMS 5-item scale Afternoon 2.35 (0.21) 2.79 (0.17) 0.11
Evening 2.75 (0.35) 2.81 (0.19) 0.89
Sleep Total night sleep time (min) 426.20 (30.40) 342.13 (27.64) 0.05
Latency
c (min) 70.39 (25.85) 51.90 (12.44) 0.52
# of awakenings at night 2.96 (0.35) 5.78 (0.59) <0.001
Quality
b (range 0–10) 6.74 (0.57) 4.65 (0.59) 0.01
Depth
b (range 0–10) 6.50 (0.50) 4.93 (0.57) 0.04
Current sleepiness
b (range 0–10) 4.33 (0.63) 5.13 (0.64) 0.38
Table 1 Effect of eszopiclone
vs placebo on pain, fatigue, and
sleep
aHigh scores indicate worse
symptoms (e.g., 1=no pain,
10=worst imaginable pain)
bHigh scores indicate better sleep
(e.g., 0=poor sleep quality,
10=excellent sleep quality)
cAfter removing one outlier with
value >400 min, the mean (SEM)
were eszopiclone 50.88 (17.78)
min vs placebo 51.90 (12.44) min;
p=0.96
dp values based on t test (non-
parametric two-sample tests gave
similar results)
2018 Support Care Cancer (2011) 19:2015–2020an expected observation because the minimum effective
analgesic dose for the same procedure is highly variable
[18]. It is possible that an effect on self-administered PCA
dosing might be observed with a longer observation period
or a different PCA dosing regimen.
This study is limited by its short-term period of observa-
tion. The pre-specified design contrasted active treatment
with placebo over a 2-day interval. We have no data on our
patients’ fatigue, pain, or sleep after they completed the trial.
It would be important to know if these observations could be
replicated and extended in a longer-term clinical trial. While
this short clinical trial is a limitation, it is important to note
that this double-blind study found that the sedative hypnotic
drug was associated with consistently decreased reports of
pain in the morning, the afternoon, and the evening—an
average reduction of pain reports by ∼30%. In addition, the
active treatment did not increase patients’ daytime fatigue—
always a concern in cancer patients who already have high
fatigue levels. Furthermore, the active drug had clear
Fig. 3 Effects of eszopiclone on pain. Mean ± SEM pain score by
time of day and treatment arm; pain score for each patient at each time
point is the average score across 2 days
Effect of Eszopiclone on length of sleep and nighttime awakenings
Mean ±SEM minutes of sleep per night by treatment arm. Mean ±SEM of number of night-time awakenings.
Effect of Eszopiclone on sleep quality and sleep depth
Mean ±SEM of sleep quality [scored on a 0 (poor) to 10 
(excellent) scale]
Mean ±SEM of sleep depth [scored on a 0 (very light) to 10 
(very deep) scale]
Fig. 2 Sleep effects
Support Care Cancer (2011) 19:2015–2020 2019beneficial effects on patients’sleep. On the one hand, it is not
surprising that a hypnotic drug would improve sleep reports;
on the other hand, the fact that one can demonstrate benefits
in this context—painful oral mucositis in patients who are
hospitalized—is a promising observation. We feel our
observations are an important first step in improving
symptom control. Natural next steps would entail replication
and extension to longer duration clinical trials and perhaps
other settings of pain.
The literature has generally focused on effects of sedative
hypnotic agents on sleep in insomniac patients or on the side
effect and safety profile. Our findings suggest that such
agents may be helpful in patients who are quite medically ill
andinpain.Eveninsuchpatients,sleepreportsareimproved,
and interestingly, pain reports are diminished. Replication of
this sort of study in other inpatients, perhaps no longer
restricted to those requiring PCA devices, would be impor-
tant. Similarly, future study might well examine the effects of
sedative hypnotic medications on quality of life in patients
with other major medical illnesses and pain.
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